ObsEva Stock Forecast, Price & News

ObsEva (NASDAQ:OBSV) Frequently Asked Questions

Is ObsEva a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ObsEva stock.
View analyst ratings for ObsEva or view top-rated stocks.

How has ObsEva's stock price been impacted by Coronavirus?

ObsEva's stock was trading at $2.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OBSV shares have decreased by 6.6% and is now trading at $2.40.
View which stocks have been most impacted by COVID-19.

Are investors shorting ObsEva?

ObsEva saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,300,000 shares, an increase of 21.1% from the October 31st total of 1,900,000 shares. Based on an average trading volume of 805,700 shares, the short-interest ratio is currently 2.9 days. Approximately 3.8% of the shares of the company are sold short.
View ObsEva's Short Interest.

When is ObsEva's next earnings date?

ObsEva is scheduled to release its next quarterly earnings announcement on Friday, March 4th 2022.
View our earnings forecast for ObsEva.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) posted its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.23.
View ObsEva's earnings history.

What price target have analysts set for OBSV?

3 equities research analysts have issued 1-year target prices for ObsEva's stock. Their forecasts range from $5.00 to $21.00. On average, they anticipate ObsEva's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 469.4% from the stock's current price.
View analysts' price targets for ObsEva or view top-rated stocks among Wall Street analysts.

Who are ObsEva's key executives?

ObsEva's management team includes the following people:

• Brian O'Callaghan, Chief Executive Officer & Director
• David Renas, Chief Financial Officer
• Jean-Pierre Gotteland, Chief Scientific Officer, Head-R&D
• Elizabeth Ijeoma Onyemelukwe Garner, Chief Medical Officer
• Elke Bestel, VP, Head-Drug Safety & Pharmacovigilance

Who are some of ObsEva's key competitors?

Some companies that are related to ObsEva include Akero Therapeutics (AKRO), Zogenix (ZGNX), Silence Therapeutics (SLN), Northwest Biotherapeutics (NWBO), Kezar Life Sciences (KZR), Chinook Therapeutics (KDNY), Atea Pharmaceuticals (AVIR), CytoDyn (CYDY), Catalyst Pharmaceuticals (CPRX), Tyra Biosciences (TYRA), Dyne Therapeutics (DYN), VBI Vaccines (VBIV), Prelude Therapeutics (PRLD), Cara Therapeutics (CARA) and Theravance Biopharma (TBPH).
View all of OBSV's competitors.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

Who are ObsEva's major shareholders?

ObsEva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Credit Suisse AG (1.52%), Cutter & CO Brokerage Inc. (0.26%), Morgan Stanley (0.24%), Goldman Sachs Group Inc. (0.16%), Geode Capital Management LLC (0.14%) and Citadel Advisors LLC (0.00%).

Which institutional investors are selling ObsEva stock?

OBSV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Citadel Advisors LLC, Barclays PLC, and Cubist Systematic Strategies LLC.

Which institutional investors are buying ObsEva stock?

OBSV stock was purchased by a variety of institutional investors in the last quarter, including Toroso Investments LLC, Geode Capital Management LLC, Credit Suisse AG, GSA Capital Partners LLP, Cutter & CO Brokerage Inc., and Goldman Sachs Group Inc..

How do I buy shares of ObsEva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $2.40.

How much money does ObsEva make?

ObsEva has a market capitalization of $187.13 million and generates $20 thousand in revenue each year. The company earns $-82.97 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does ObsEva have?

ObsEva employs 45 workers across the globe.

What is ObsEva's official website?

The official website for ObsEva is www.obseva.com.

Where are ObsEva's headquarters?

ObsEva is headquartered at Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at (122) 552-3840 or via email at [email protected].